Skip to main content
. Author manuscript; available in PMC: 2014 Mar 18.
Published in final edited form as: Gen Med (Los Angel). 2013 Aug 27;1(3):112. doi: 10.4172/2327-5146.1000112

Figure 2.

Figure 2

Experimental strategy for using chemical genetics with the zebrafish embryo to screen for AKI-relevant therapeutics. (A) Zebrafish embryos are arrayed in 96-well plates (or other multi-well plates) and exposed to drugs in a temporally-controlled fashion during development, in which the researcher adds the drug at the time of interest. (B) Embryos are examined for subsequent phenotypic alterations, such as the rescue of edema associated with AKI. Zebrafish embryos are optically transparent, and develop minimal pigmentation by 3–5 days of development, which facilitates the visualization of internal organs. Compared to a wild type embryo (bottom), an embryo exposed to gentamicin (top) develops AKI symptoms that include pericardial edema, seen as a swelling around the heart adjacent to the yolk sac.